Cortistatin Peptide: Preclinical Research Guide

For laboratory and research use only. Not for human consumption.

Cortistatin is a neuropeptide studied in the research literature primarily for its close structural relationship to somatostatin and for a receptor-binding profile that also includes the ghrelin receptor, a property somatostatin itself does not share. This overview summarizes what published research describes about the compound's structure, proposed receptor mechanism, and preclinical findings in sleep/EEG and immune-signaling model systems, and clarifies its current research-use status.

Key Facts

Cortistatin was first identified in the rat cerebral cortex in 1996 as a cyclic neuropeptide expressed in a distinct subset of GABAergic interneurons, partially overlapping with those expressing somatostatin.
The literature describes the mature peptide (cortistatin-14 in rodents; cortistatin-17 in humans) as sharing the majority of its amino acid residues with somatostatin, including the paired cysteines that form its cyclic disulfide structure.
Research literature reports that Cortistatin binds all five cloned somatostatin receptor subtypes (SSTR1-5) with an affinity profile similar to somatostatin.
Unlike somatostatin, Cortistatin is also reported in the literature to bind the ghrelin receptor (GHSR), a receptor-binding property considered functionally distinctive to Cortistatin among this peptide family.
Preclinical findings come primarily from rodent and cell-based studies examining EEG/sleep architecture and immune-signaling model systems, not human clinical trials.
Cortistatin is not FDA-approved for human or veterinary use and is sold exclusively for laboratory research applications.

What Is Cortistatin?

Cortistatin was first described in 1996 following its identification in rat cerebral cortex tissue, where it is expressed by a subpopulation of GABAergic interneurons in the cortex and hippocampus that partially overlaps with the population expressing somatostatin. The peptide is processed from a larger precursor protein (preprocortistatin) into shorter mature forms; the literature refers to cortistatin-14 as the predominant rodent form and cortistatin-17 as the corresponding human form, with a related cortistatin-29 fragment also described. Structurally, cortistatin is characterized as a cyclic peptide, with a disulfide bridge formed between a pair of cysteine residues, and research literature notes that the majority of its amino acid sequence is identical to that of somatostatin. This close sequence homology is the basis for cortistatin's overlapping receptor pharmacology with somatostatin, while a smaller set of non-shared residues is associated in the literature with the receptor-binding properties that distinguish the two peptides from one another.

Proposed Mechanism: Somatostatin- and Ghrelin-Receptor Binding

Research literature describes cortistatin as binding, in vitro, to all five cloned somatostatin receptor subtypes (SSTR1 through SSTR5) with an affinity profile broadly similar to somatostatin itself, consistent with the two peptides' shared sequence homology. What distinguishes cortistatin in the literature is a broader receptor-binding footprint: unlike somatostatin, cortistatin is also reported to bind the ghrelin receptor (GHSR, also referenced as GHS-R1a), a G-protein-coupled receptor that somatostatin does not engage. This ghrelin-receptor interaction is described as a defining pharmacological feature of cortistatin among the somatostatin-related peptide family. At the electrophysiological level, in vitro studies applying cortistatin to hippocampal slice preparations describe hyperpolarization of CA1 pyramidal neurons and an enhancement of the M-current, an effect reported in the literature as distinct from somatostatin's own electrophysiological profile and proposed as a contributor to cortistatin's effects on cortical excitability.

What Preclinical and Animal-Model Research Has Measured

Published research on cortistatin spans two research areas that recur most frequently in the literature: central nervous system studies of sleep and cortical electrical activity, and peripheral studies of immune and inflammatory signaling. These studies have measured outcomes such as:

EEG slow-wave activity and time spent in slow-wave (non-REM) sleep in rodents following intracerebroventricular administration of cortistatin, assessed through polysomnographic recording.
Electrophysiological changes in hippocampal neurons, including membrane hyperpolarization and M-current amplitude, measured in ex vivo brain-slice preparations.
Circulating and tissue cytokine levels, such as interleukin-1beta, interleukin-6, interferon-gamma, and tumor necrosis factor-alpha, measured by immunoassay in rodent models of sepsis and other inflammatory conditions.
Immune-cell activity, including T-cell proliferation and macrophage-derived chemokine secretion, assessed in cell-culture and animal-model systems modeling autoimmune and inflammatory disease.
Disease-severity and organ-pathology scores in rodent models of conditions such as arthritis, inflammatory bowel disease, and autoimmune encephalomyelitis, assessed through histological and clinical scoring systems specific to each model.

These findings are specific to the model systems and study designs in which they were generated. They describe what researchers observed in those cell and animal models under controlled laboratory conditions, and do not constitute evidence about outcomes in humans. Published discussions of cortistatin also note practical constraints on the compound in preclinical work, including a short half-life in biological fluids, which researchers account for in study design.

Research-Use Status

Cortistatin has not been approved by the FDA or any comparable regulatory authority for use in humans or animals outside of a research setting. It is manufactured, sold, and handled strictly as a research compound intended for laboratory applications such as in vitro assays and animal-model studies conducted under appropriate institutional protocols. Any research use should follow the handling, storage, and documentation practices appropriate to the specific study protocol involved, including verification of identity and purity via the compound's Certificate of Analysis before use in an experiment.

Related Neuropeptide and Receptor-Pathway Research Overviews

Cortistatin sits at the intersection of two research areas covered elsewhere on this site. For a look at another neuropeptide studied specifically for its effects on sleep architecture, see our DSIP and sleep research overview, which covers a structurally unrelated peptide investigated in a similar sleep-research context. Researchers interested in the ghrelin-receptor side of cortistatin's pharmacology may also find our GHRP-2 research overview useful as a comparison point, since GHRP-2 is studied for its direct action at the same ghrelin receptor (GHS-R1a) that cortistatin is reported to bind.

Before beginning any laboratory work with cortistatin, reviewing batch-specific identity and purity documentation is an important first step; our testing and COA transparency page outlines how we verify the research materials we supply. For calculating a working concentration from a reconstituted vial ahead of an assay, our reconstitution calculator is available as a reference tool.

Frequently Asked Questions

What is Cortistatin?

Cortistatin is a cyclic neuropeptide first identified in the rat cerebral cortex, expressed in a subset of GABAergic interneurons, and studied in the literature for its close structural homology to somatostatin as well as a distinct receptor-binding profile that includes the ghrelin receptor.

What mechanism does research literature propose for Cortistatin?

Published studies describe Cortistatin as binding all five cloned somatostatin receptor subtypes (SSTR1-5) with an affinity profile similar to somatostatin, while also binding the ghrelin receptor (GHSR), a non-somatostatin receptor that somatostatin itself does not engage, giving Cortistatin a broader and functionally distinct receptor-signaling footprint in model systems.

What have animal-model studies measured regarding Cortistatin's role in sleep and neural activity?

Animal-model studies referenced in the literature have measured EEG slow-wave activity and time spent in slow-wave sleep in rodents following intracerebroventricular administration of Cortistatin, alongside electrophysiological measures such as neuronal hyperpolarization and M-current changes observed in hippocampal slice preparations.

What have studies measured regarding Cortistatin in immune and inflammatory research models?

Preclinical studies in rodent models of sepsis, arthritis, inflammatory bowel disease, and other inflammatory or autoimmune conditions have measured circulating and tissue cytokine levels, immune-cell activity such as T-cell proliferation, and disease-severity scores specific to each model following Cortistatin administration.

Is Cortistatin approved for human or veterinary use?

No. Cortistatin is not approved by the FDA or any comparable regulatory body for human or veterinary use. It is sold and studied strictly as a research compound for laboratory applications.